SAGA Diagnostics achieves ISO 17025 accreditation by SWEDAC for mutation testing services
LUND, Sweden — /June 15, 2021/ — SAGA Diagnostics AB (“SAGA”), today announced that it has successfully been accredited to the ISO 17025 standard for its leading-edge mutation detection laboratory services designed to radically improve cancer diagnosis, monitoring, and treatment outcomes. Granted by SWEDAC, the Swedish Board for Accreditation and Conformity Assessment, ISO 17025 is an international quality management standard used to assess the competency of analytical laboratories.
The entire SAGA team is delighted with achieving this milestone as it demonstrates our commitment to providing the highest quality services and results to our rapidly growing number of customers in the biotechnology, pharmaceutical, academic, and hospital sectors.
– Dr. Karolina Holm, Clinical Laboratory QA Manager of SAGA Diagnostics
SAGA is commercializing proprietary ultrasensitive technologies to quantify cancer-associated genetic aberrations in tissue and liquid biopsy samples which are uniquely capable of achieving limits of detection down to 0.001% mutant allele fraction. SAGA’s platform technologies, which are based on digital PCR and next-generation sequencing, are tools to be used in cancer patient stratification, therapy response monitoring, disease relapse identification, as well as in aiding in treatment decisions and as companion diagnostics.
CEO Lao Saal, MD PhD. firstname.lastname@example.org Phone: +46 (0) 733 01 7242
Richard Hayhurst/Ola Björkman email@example.com Phone: +44 (0) 7711 821527
About SAGA Diagnostics AB
SAGA Diagnostics is a personalized cancer genomics and disease monitoring company that offers molecular genetic testing of tissue biopsies and non-invasive “liquid biopsies” such as blood samples. SAGA helps pharmaceutical companies, scientists, and healthcare providers to detect actionable mutations, stratify patient groups, and monitor treatment response more accurately and to an industry-leading lower limit of detection of 0.001%. Analysis of circulating tumor DNA using its proprietary technologies gives SAGA unique ultrasensitivity, and provides the basis for optimal decision-making.